Randomized Controlled Trial of Rituximab and Cost‐Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome

医学 美罗华 安慰剂 可视模拟标度 内科学 风湿病 随机对照试验 临床终点 痹症科 物理疗法 外科 淋巴瘤 病理 替代医学
作者
Simon Bowman,Colin Everett,John O’Dwyer,Paul Emery,Costantino Pitzalis,Wan‐Fai Ng,Colin S. Gillespie,Elizabeth Price,Nurhan Sutcliffe,Nagui Gendi,Frances Hall,Sharon Ruddock,Catherine Fernandez,Catherine Reynolds,Claire Hulme,Kevin Davies,Christopher J Edwards,Peter Lanyon,Robert J. Moots,Euthalia Roussou,Ian Giles,Linda Sharples,Stefano Bombardieri
出处
期刊:Arthritis & rheumatology [Wiley]
卷期号:69 (7): 1440-1450 被引量:213
标识
DOI:10.1002/art.40093
摘要

To investigate whether rituximab, an anti-B cell therapy, improves symptoms of fatigue and oral dryness in patients with primary Sjögren's syndrome (SS).We conducted a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial that included health economic analysis. Anti-Ro-positive patients with primary SS, symptomatic fatigue, and oral dryness were recruited from 25 UK rheumatology clinics from August 2011 to January 2014. Patients were centrally randomized to receive either intravenous (IV) placebo (250 ml saline) or IV rituximab (1,000 mg in 250 ml saline) in 2 courses at weeks 0, 2, 24, and 26, with pre- and postinfusion medication including corticosteroids. The primary end point was the proportion of patients achieving a 30% reduction in either fatigue or oral dryness at 48 weeks, as measured by visual analog scale. Other outcome measures included salivary and lacrimal flow rates, quality of life, scores on the European League Against Rheumatism (EULAR) Sjögren's Syndrome Patient Reported Index and EULAR Sjögren's Syndrome Disease Activity Index, symptoms of ocular and overall dryness, pain, globally assessed disease activity, and cost-effectiveness.All 133 patients who were randomized to receive placebo (n = 66) or rituximab (n = 67) were included in the primary analysis. Among patients with complete data, 21 of 56 placebo-treated patients and 24 of 61 rituximab-treated patients achieved the primary end point. After multiple imputation of missing outcomes, response rates in the placebo and rituximab groups were 36.8% and 39.8%, respectively (adjusted odds ratio 1.13 [95% confidence interval 0.50, 2.55]). There were no significant improvements in any outcome measure except for unstimulated salivary flow. The mean ± SD costs per patient for rituximab and placebo were £10,752 ± 264.75 and £2,672 ± 241.71, respectively. There were slightly more adverse events (AEs) reported in total for rituximab, but there was no difference in serious AEs (10 in each group).The results of this study indicate that rituximab is neither clinically effective nor cost-effective in this patient population.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小曾应助liuHX采纳,获得10
刚刚
basepair发布了新的文献求助10
刚刚
nkmenghan发布了新的文献求助30
3秒前
cxjie320完成签到,获得积分10
3秒前
平常莹芝完成签到,获得积分10
4秒前
4秒前
Zurlliant完成签到,获得积分10
4秒前
聪慧的以彤完成签到,获得积分10
4秒前
ZDM6094完成签到 ,获得积分10
4秒前
潘潘完成签到 ,获得积分10
5秒前
隐形曼青应助YHX采纳,获得10
5秒前
清秀苗条完成签到,获得积分10
5秒前
忧心的若云完成签到,获得积分10
6秒前
大力的馒头完成签到 ,获得积分10
6秒前
Lucky.完成签到 ,获得积分0
7秒前
zheyu完成签到,获得积分10
7秒前
7秒前
自信鑫鹏完成签到,获得积分10
7秒前
skj你考六级完成签到,获得积分10
8秒前
614521发布了新的文献求助10
8秒前
慈祥的二爷完成签到,获得积分10
8秒前
8秒前
所所应助xiaoguan采纳,获得10
9秒前
有人喜欢蓝完成签到 ,获得积分10
9秒前
杨佳于完成签到,获得积分20
9秒前
王小西发布了新的文献求助10
10秒前
瓜兵是官爷完成签到,获得积分10
10秒前
何静涛完成签到,获得积分10
11秒前
黄文斌完成签到,获得积分10
11秒前
冯宇完成签到,获得积分10
12秒前
luwenxuan发布了新的文献求助10
13秒前
小琪猪完成签到,获得积分10
13秒前
basepair完成签到,获得积分10
13秒前
啦哈啦哈啦完成签到,获得积分10
14秒前
活力毛豆完成签到 ,获得积分10
14秒前
x_x完成签到,获得积分10
14秒前
李雪松完成签到 ,获得积分10
14秒前
柚子完成签到,获得积分10
15秒前
sunflowers完成签到 ,获得积分10
15秒前
15秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038303
求助须知:如何正确求助?哪些是违规求助? 3576013
关于积分的说明 11374210
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029